Gerrit Schipper, MD
Obstetrics & Gynecology · Frederick, MDNPI 1134101884
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Organon at 52.2% of the total. Reporting peaked in 2021 at $7,200 and has fallen 92.5% since, to $539 in 2025. Among obstetrics & gynecology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $74.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$9K
- Renovia Inc$2K
- Merck$1K
- AbbVie$795
- Coloplast$579
- Astellas Pharma US Inc$574
- plus $3K from 32 others
Across 29 payments — averaging $3214.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$31K
- Bayer$26K
- Boston Scientific$21K
- Mylan Inc.$15K
- Mylan Technologies Inc.$61
What the payments were for
- Consulting fees$6003%
- Speaking & faculty fees$10,18359%
- Travel & lodging$5273%
- Food & beverage$5,54632%
- Education$3352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 17 | $8,972 |
| Renovia Inc | 21 | $1,996 |
| Merck | 5 | $1,477 |
| AbbVie(2 entities) | 33 | $795 |
| Coloplast | 6 | $579 |
| Astellas Pharma US Inc | 15 | $574 |
| Mayne Pharma Commercial LLC | 25 | $420 |
| Bayer | 16 | $314 |
| Sumitomo Pharma America, Inc. | 14 | $251 |
| Daiichi Sankyo Inc. | 4 | $229 |
| Therapeuticsmd, Inc. | 9 | $228 |
| AMAG Pharmaceuticals, Inc. | 6 | $169 |
| Aspira Women's Health Inc | 4 | $125 |
| Amgen | 7 | $123 |
| Johnson & Johnson | 5 | $119 |
| Caldera Medical, Inc | 2 | $85 |
| Coopersurgical, Inc. | 5 | $83 |
| Hologic Sales And Service, LLC | 4 | $77 |
| Millicent US Inc | 5 | $67 |
| Axonics, Inc. | 4 | $67 |
| KCI USA, Inc. | 2 | $44 |
| Acella Pharmaceuticals, LLC | 2 | $42 |
| Sage Therapeutics, LLC | 2 | $39 |
| AstraZeneca | 2 | $32 |
| Smith+Nephew | 2 | $29 |
| Evofem Biosciences, Inc. | 2 | $28 |
| Shield Therapeutics Inc | 1 | $26 |
| Minerva Surgical, Inc | 1 | $25 |
| Optumhealth Care Solutions, LLC | 1 | $24 |
| Lumenis, Inc | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Vertex | 1 | $17 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,191 in reported general payments places this provider in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 14 | $19,531 |
| Estradiol | 193 | $16,447 |
| MyrbetriqMirabegron | 14 | $15,527 |
| EstringEstradiol | 15 | $7,803 |
| YuvafemEstradiol | 37 | $7,651 |
| Solifenacin Succinate | 49 | $5,226 |
| Raloxifene Hcl | 26 | $2,705 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $976 |
| ProgesteroneProgesterone, Micronized | 26 | $968 |
| ValacyclovirValacyclovir Hcl | 13 | $759 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $703 |
| Clobetasol Propionate | 13 | $634 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $295 |
| Cephalexin | 11 | $142 |
| Scopolamine | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $251 | $19,53114 claims |
| Astellas Pharma US IncMyrbetriq | $574 | $15,52714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.
Other obstetrics & gynecology in Frederick
- Leonard BienkowskiFrederick$6K
- Tasscia Williams SouffrantFrederick$6K
- Otis StittSilver Spring$641K
- Danielle ShillerBaltimore$221K
- Matthew ReevesChevy Chase$149K
- Karen WangBaltimore$91K
- Rebecca StoneBaltimore$88K
- Abigail GregoryOakland$63K
- Christina EnzmannBaltimore$63K
- Lisa RarickChesapeake Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.